Compare AstraZeneca plc (AZN) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs CarMax, Inc — how do they compare? AstraZeneca plc trades at $168.39 (market cap $253.13B), while CarMax, Inc trades at $59.14 (market cap $7.91B). The key difference: AstraZeneca plc is far larger — about 32× CarMax, Inc's market cap, and AstraZeneca plc pays a 1.92% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.
| AZN | KMX | |
|---|---|---|
Market Cap | $253.13B | $7.91B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $63.53 |
52-Week Low | $137.44 | $30.88 |
Enterprise Value | $279.37B | $26.42B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
CarMax (KMX) trades at $54.87, up 2.58% today, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported Q1 2026 earnings that beat expectations, with EPS of $0.34 versus $0.23 expected, driven by cost controls and strategic execution. Revenue for 2025 was $26.35 billion, with net income of $500.56 million, though margins remain thin. Recent news highlights a four-pillar turnaround strategy under new CEO Keith Barr, with insider buying and positive analyst updates supporting sentiment.
The outlook for KMX hinges on successful execution of its growth strategy amid competitive pressures and margin challenges. While technical indicators suggest near-term strength, fundamental risks include high debt levels and fluctuating profitability. Analyst consensus is cautious with a hold-heavy rating, but the stock offers potential for recovery if operational improvements sustain. Investors should weigh the bullish technical setup against fundamental headwinds and ongoing investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
